|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1) has been implicated as a powerful pro-inflammatory mediator and may represent a potentially important, therapeutic opportunity for treatment of inflammatory disease and atherosclerosis.
|
11591377 |
2001 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein 1 (MCP-1) and the receptor for MCP-1, CCR2, play a pivotal role in the recruitment of monocytes to the subendothelium, which is the initial event in atherosclerosis.
|
13678532 |
2003 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1) plays an important role in atherosclerosis.
|
14620921 |
2003 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice.
|
14739122 |
2004 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1; gene name CCL2) has been suggested to play an important role in the initiation of atherosclerosis by recruiting monocytes to sites of injured endothelium.
|
18230355 |
2008 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1:CCL2) has been demonstrated to be involved in the pathophysiology of atherosclerosis and hypertension.
|
18977211 |
2009 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MCP-1 gene A-2518G polymorphism and carotid artery atherosclerosis in patients with type 2 diabetes.
|
19781803 |
2009 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1) and its receptor chemokine (C-C motif) receptor 2 (CCR2) are implicated in promoting atherosclerosis.
|
21868018 |
2011 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1) is a potent chemokine and plays an important role in atherosclerosis of Type 2 diabetes.
|
21975431 |
2012 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1) plays crucial roles at multiple stages of atherosclerosis.
|
23402987 |
2013 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1) is an important chemokine at multiple phases of atherosclerosis in animals, but human studies are few and inconsistent.
|
25786118 |
2015 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1), as a critical factor for monocyte infiltration, is known to play a role in the development of atherosclerosis.
|
26354107 |
2016 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein 1 (MCP1) with recruiting monocytes is an important factor at the beginning of inflammatory disorders such as atherosclerosis which seems its blocking preclude this process and help improvement of related diseases.
|
29596634 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
MCP-1 did not correlate with intermediate CV outcomes, implicating pathways other than atherosclerosis in the association of MCP-1 with death in CKD.
|
29874658 |
2018 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MCP-1 and FGF-21 levels are associated with subclinical atherosclerosis disease severity (i.e., cIMT) in postmenopausal women without CVD.
|
31152776 |
2019 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1) is a proinflammatory cytokine that plays a key role in the development of atherosclerosis.
|
31388753 |
2019 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CCL2 expression was associated with a significant predictive value of atherosclerosis.
|
31739217 |
2020 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Monocyte chemoattractant protein-1 (MCP-1) is a potent agonist for mononuclear leukocytes and has been implicated in the pathogenesis of atherosclerosis and granulomatous lung disease.
|
9366570 |
1997 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A three-dimensional in vitro model to demonstrate the haptotactic effect of monocyte chemoattractant protein-1 on atherosclerosis-associated monocyte migration.
|
28041913 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although plasma/serum levels of certain chemokines (eg, interleukin- 8/CXCL8 and monocyte chemoattractant protein-1/CCL2) have shown to be predictive for future cardiac events in some studies, their role as clinical biomarkers is unclear, and their ability to predict subclinical atherosclerosis has been disappointing.
|
18669888 |
2008 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the serum MCP-1 concentration is higher in patients with than without cardiovascular disease, the precise correlations between the serum MCP-1 concentration and factors associated with smoking and atherosclerosis are unknown.
|
29098933 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
LHGDN |
An increase in MCP-1 may be an important factor in the progression of atherosclerosis in non-diabetic HD patients.
|
15226634 |
2004 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Atheroprotective Mechanisms Activated by Fluid Shear Stress in Endothelial Cells.
|
12677255 |
2002 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Based on our findings, we suggest that Nrf2-dependent HO-1 expression induced by HA inhibits MCP-1 secretion, VCAM-1 expression and NF-kappaB activation associated with vascular injury and inflammation in atherosclerosis.
|
16246346 |
2006 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Canagliflozin attenuates the progression of atherosclerosis, reducing (1) hyperlipidemia and hyperglycemia, and (2) inflammatory process, by lowering the expression of inflammatory molecules such as MCP-1 and VCAM-1.
|
30049285 |
2018 |